We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0A9G market cap is 0. The company's latest EPS is GBP and P/E is N/A.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 0 | 2.56M | 0 | 36.46M | 811k |
| Operating Income | -35.21M | -36.96M | -37.57M | -20.94M | -42.76M |
| Net Income | -32.03M | -34.84M | -163.63M | 12.73M | -34.2M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 67.28M | 86.45M | 62.95M | 126.42M | 88.08M |
| Total Liabilities | 34.51M | 46.19M | 77.92M | 38.42M | 26.21M |
| Total Equity | 32.77M | 40.26M | -14.97M | 88M | 61.87M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -23.14M | -45.93M | -28.34M | -5.24M | -38.82M |
| Investing | 251k | 43.3M | 1.5M | -421k | 1.5M |
| Financing | -2.07M | -5.71M | 34.74M | 77.65M | -784k |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 624.93M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Mereo Biopharma Group Plc |
| Address |
fourth floor london W1G 0QF |
| Website | https://www.mereobiopharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
